Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation

Figures & data

Table 1 Characteristics of 4 advanced lung adenocarcinoma patients administered apatinib therapy

Characteristics	Patient 1	Patient 2	Patient 3	Patient 4
Age, years	56	81	73	62
Sex	Male	Male	Male	Male
Stage	IV (T2N2M1b)	IV (T2N2M1b)	IV (T4N3M1b)	IV (T3N2M1b)
Treatment (response)
First-line	Plat + Pem (SD)	Pem (SD)	Carb + Pem (SD)	Carb + Pem (SD)
Second-line	Docetaxel (SD)	Docetaxel (PD)	Docetaxel (SD)	Docetaxel (PD)
Third-line	Apatinib (SD)	Apatinib (SD)	Gefitinib (PD)	Apatinib (PD)
Fourth-line	–	–	Apatinib (SD)	–
Apatinib PFS	4.5 months	1.5 months	5.5 months	–
Adverse effects	–	Hemoptysis (Grade 1)	–	–

Abbreviations: Carb, carboplatin; Plat, platinum; PD, progressive disease; Pem, pemetrexed; PFS, progression-free survival; PR, partial response; SD, stable disease.

Figure 1 Representative CT images (lung windows and mediastinal windows) of two patients before and after apatinib monotherapy.

Notes: CT images of Patient 1 showed progressive disease response. CT images of Patient 2 showed stable disease response. Pre- and post-apatinib images at the (A, C) lung and (B, D) mediastinal windows for Patients 1 and 2, respectively. The red arrows indicate the tumor variations before and after apatinib therapy.
Abbreviation: CT, computed tomography.